Recognitions, Board Elections, Acquisitions, and Organizational Changes - Analyst Notes on Omnicare, Cooper, Mednax, IDEXX, and Hologic

NEW YORK, March 27, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Omnicare Inc. (NYSE: OCR), The Cooper Companies Inc. (NYSE: COO), MEDNAX, Inc. (NYSE: MD), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Hologic Inc. (NASDAQ: HOLX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Omnicare Inc. Analyst Notes 

On March 21, 2014, Omnicare Inc. (Omnicare) announced that Advanced Care Scripts (ACS), a division of Omnicare Specialty Care Group, has been awarded Specialty Pharmacy Accreditation from URAC. URAC is a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry. "ACS is proud to receive this accreditation," said Amit Jain, Senior Vice President of Sales and Marketing. "We are dedicated to providing quality care and meeting the highest industry standards for our customers and patients." ACS manages and dispenses specialty medications in multiple disease categories, including cancer, infectious diseases, auto-immune disorders, multiple sclerosis and hemophilia. The full analyst notes on Omnicare Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03272014/OCR/report.pdf

--

The Cooper Companies Inc. Analyst Notes 

On March 17, 2014, The Cooper Companies Inc. (Cooper) announced at its annual meeting held on March 17, 2014, that the stockholders of the Company elected eight directors: A. Thomas Bender, Allan E. Rubenstein, M.D., Michael H. Kalkstein, Jody S. Lindell, Gary S. Petersmeyer, Steven Rosenberg, Robert S. Weiss, and Stanley Zinberg, M.D. and ratified the appointment of KPMG LLP as the Company's auditors for FY 2014. The stockholders also approved, on an advisory basis, the Company's compensation practices for its executive officers. The full analyst notes on The Cooper Companies Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03272014/COO/report.pdf

--

MEDNAX, Inc. Analyst Notes 

On March 4, 2014, MEDNAX Inc. (MEDNAX) announced that it has acquired Piedmont Neonatology, P.C., a private neonatal physician group practice based in Greensboro, N.C. The practice will become part of MEDNAX's Pediatrix Medical Group division, a national group practice consisting of the nation's leading neonatal, maternal-fetal medicine, pediatric cardiology, and other pediatric specialty physicians. The practice was acquired for cash and the transaction is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed. The full analyst notes on MEDNAX, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03272014/MD/report.pdf

--

IDEXX Laboratories, Inc. Analyst Notes 

On March 11, 2014, IDEXX Laboratories, Inc. (IDEXX) announced the election of Daniel M. Junius as a member of the Company's Board of Directors, effective March 11, 2014. "I am very pleased and excited to welcome Daniel Junius to our Board of Directors," said Jonathan Ayers, the Company's Chairman of the Board and CEO. "Dan brings an impressive depth of executive leadership, strategic thinking and financial experience as well as extensive biotechnology knowledge, which the Company will benefit from as it continues to strengthen and grow its business and capitalize on its opportunities." Mr. Junius previously served as President and CEO of ImmunoGen, Inc. The full analyst notes on IDEXX Laboratories, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03272014/IDXX/report.pdf

--

Hologic Inc. Analyst Notes 

On March 14, 2014, Hologic, Inc. (Hologic) announced organizational and leadership changes in order to achieve its corporate objectives including organic growth and executional excellence across its global operations. The Company appointed Eric Compton to the role of Chief Operating Officer and will be responsible for overseeing all of the Company's commercial operations in the US, as well as the Company's global research and development, manufacturing and service operations. Claus Egstrand has been named Senior Vice President and General Manager, International, and will be responsible for the Company's operations outside of the United States. David Harding, who previously served as Hologic's Group Senior Vice President and General Manager of Women's Health, has been named Senior Vice President of Corporate Strategy. The full analyst notes on Hologic Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03272014/HOLX/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review